GLP-1 Receptor Agonists and Dermatologic Outcomes in Type 2 Diabetes

Key Takeaways

• Compared with DPP-4 inhibitor initiation, GLP-1 receptor agonist initiation was associated with higher psoriasis risk and lower pemphigus and bullous pemphigoid risk.
• Other inflammatory or autoimmune skin outcomes were not significantly different after multiple-testing correction.
• The analysis emulated an active-comparator trial in matched adults with type 2 diabetes, followed patients for up to 4 years, and showed similar results in subgroup and sensitivity analyses.

In a large real-world comparison of adults with type 2 diabetes, a Frontiers in Endocrinology study linked GLP-1 receptor agonist initiation to roughly 19% higher psoriasis risk versus DPP-4 inhibitors. The comparison focused on adults with type 2 diabetes starting one of two commonly used incretin-based strategies in routine care.

The analysis used the TriNetX US Collaborative Network in a large real-world active-comparator target trial emulation. Adults with type 2 diabetes who started GLP-1 receptor agonists or DPP-4 inhibitors between January 1, 2018, and December 31, 2022, were eligible. Investigators excluded prior users of either class and used 1:1 propensity score matching to create balanced cohorts of 169,630 patients in each group. Outcomes within 3 months after treatment initiation were set aside to reduce protopathic bias, and follow-up continued for as long as 4 years. Cox regression generated hazard ratios with 95% confidence intervals, and the comparison remained a matched observational emulation rather than a randomized trial.

In the matched analysis, outcome estimates separated into one increased association and two decreased associations among the highlighted dermatologic conditions. Investigators found a higher risk of incident psoriasis with GLP-1 receptor agonist initiation, HR 1.19 (95% CI 1.11-1.28). They also observed lower risks of pemphigus, HR 0.32 (95% CI 0.16-0.63), and bullous pemphigoid, HR 0.61 (95% CI 0.43-0.87). Other inflammatory or autoimmune skin outcomes did not differ significantly after multiple-testing correction across the remaining reported categories. These differences appeared confined to selected conditions rather than spread across the broader dermatologic outcome set.

The associations persisted across subgroup and sensitivity analyses, showing consistency across the analytic checks described in the abstract. The concluding language placed the findings within the dermatologic safety profile surrounding incretin therapy and noted the relevance of ongoing skin monitoring.